

Press Release – For immediate release

BIOLIDICS' LABORATORY PARTNER IN CHINA TO LAUNCH A COMMERCIAL LABORATORY-DEVELOPED TEST SERVICE OF PD-L1 USING CLEARCELL® FX1 SYSTEM AND CTCHIP® FR1 BIOCHIP

- **Programmed death-ligand 1 ("PD-L1") proteins prevent an individual's immune system from attacking the cancer cells and cancer drug treatments are used to target and block PD-L1 proteins**
- **An average number of over 10,000 patients diagnosed with cancer per day in China in 2015⁽¹⁾**
- **The incidence of cancer in China has increased at 3.9% annually, while the country's mortality rate for cancer increased at 2.5% annually⁽¹⁾**
- **The commercial laboratory-developed test ("LDT") service of PD-L1 by Hunan Agen Lab, using Biolidics' ClearCell® FX1 System and CTChip® FR1 biochip, will enable oncologists to better understand if the patient is responding positively to the cancer treatment**

Singapore, 11 November 2019 – Biolidics Limited ("Biolidics" or the "Company"), a medical technology company with a focus on cancer diagnostic solutions, is pleased to announce that its laboratory partner, Hunan Agen Medicine Laboratory Technology Co., Ltd. ("Hunan Agen Lab"), has launched a commercial LDT service, using Biolidics' ClearCell® FX1 System and CTChip® FR1 biochip, to test the status of PD-L1 in cancer patients and this service is commercially available in China.

According to the Chinese Journal of Oncology published in January 2019, the number of cancer patients in China is on the rise and the annual expenditure on relevant medical services is estimated at RMB 220 billion, indicating that China's increasingly aging population is the leading cause of its cancer burden.

Cancer generally requires long periods of treatment and as patients undergo cancer drug treatments, there is a need to monitor the efficacy of the treatment so as to improve the clinical outcomes of the treatment.

PD-L1 is a protein which prevents our immune system from attacking healthy cells in our body. Some cancer cells may also express PD-L1 protein markers and evade detection by our immune system. With just a blood sample, this diagnostic test measures the amount of PD-L1 expressed by cancer cells, thereby enabling physicians to gain more insights on how the patient potentially responds to PD-1/PD-L1 immune checkpoint inhibitors.

(1) <http://www.chinadaily.com.cn/a/201902/15/WS5c663581a3106c65c34e9904.html>

The potential demand for such LDT service is expected to lead to higher usage of ClearCell® FX1 System and increased demand of our single-use CTChip® FR1 biochips.

Based in the Changsha High-Tech Development Zone, Hunan Agen Lab provides multidisciplinary diagnostics, including clinical cellular and molecular genetics, clinical pathology, clinical immunology, clinical biochemistry, and advanced equipment such as Next Generation Sequencing.

Earlier in March 2019, Hunan Agen Lab started offering a LDT related to circulating tumour cells (“CTCs”) as clinical services to cancer patients, which also utilise Biolidics’ ClearCell® FX1 System and CTChip® FR1 biochips. The presence of CTCs is a fundamental prerequisite to metastasis, which is responsible for an estimated 90% of cancer deaths and it is the process where cancer cells spread through the blood and lymph systems from the place where they first formed.

- END -

About Biolidics Limited

(Bloomberg Code: BLD:Singapore / Reuters Code: BIOL.SI / SGX Code: 8YY)

Incorporated in 2009, Biolidics is a Singapore-based medical technology company focusing on the development of cell enrichment systems which, when combined with other analytical tests, have a wide range of applications for cancer diagnosis, prognosis, treatment selection and treatment monitoring.

Biolidics has developed and commercialised the ClearCell® FX1 System, a fully automated CE-IVD medical device which relies on a novel patented technology to separate and enrich cancer cells from blood.

The ClearCell® FX1 System, installed across Asia, Europe and North America, allows users of the system to perform liquid biopsies to test for the presence of cancer cells (specifically circulating tumour cells, or CTCs) in blood samples or perform further analysis on cancer cells.

Liquid biopsies (i.e. analysis of the circulating tumour cells in blood samples) have many applications throughout the various stages of a patient's cancer journey, from cancer screening and staging to personalised treatment, and post- cancer monitoring.

Biolidics’ quality assurance capabilities have been recognised through its ISO 13485 certification, CE-IVD, US FDA Class I registration and NMPA (formerly CFDA) Class I registration.

For additional information, please visit www.biolidics.com.

Issued on behalf of Biolidics Limited by 8PR Asia Pte Ltd.

Media & Investor Contacts:



Mr. Alex TAN
Mobile: +65 9451 5252
Email: alex.tan@8prasia.com

This press release has been prepared by Biolidics Limited (the "Company") and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist. This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.